Argenica Therapeutics Past Earnings Performance
Past criteria checks 0/6
Argenica Therapeutics's earnings have been declining at an average annual rate of -34%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 75.7% per year.
Key information
-34.0%
Earnings growth rate
-9.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 75.7% |
| Return on equity | -39.3% |
| Net Margin | -210.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Sep 23
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth
Jan 12Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Jul 20Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Apr 20We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Nov 30Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Aug 12Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Apr 29Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Dec 30We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Sep 16Revenue & Expenses Breakdown
How Argenica Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -5 | 2 | 6 |
| 31 Mar 24 | 3 | -5 | 2 | 6 |
| 31 Dec 23 | 3 | -5 | 2 | 5 |
| 30 Sep 23 | 2 | -5 | 2 | 5 |
| 30 Jun 23 | 2 | -5 | 2 | 4 |
| 31 Mar 23 | 2 | -4 | 2 | 4 |
| 31 Dec 22 | 1 | -4 | 2 | 3 |
| 30 Sep 22 | 1 | -4 | 2 | 3 |
| 30 Jun 22 | 0 | -4 | 2 | 2 |
| 31 Mar 22 | 0 | -3 | 2 | 2 |
| 31 Dec 21 | 0 | -3 | 2 | 1 |
| 30 Sep 21 | 0 | -2 | 1 | 1 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
Quality Earnings: AGN is currently unprofitable.
Growing Profit Margin: AGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGN is unprofitable, and losses have increased over the past 5 years at a rate of 34% per year.
Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: AGN has a negative Return on Equity (-39.28%), as it is currently unprofitable.